| DCTN1 — Dynactin Subunit 1 | |
|---|---|
| Symbol | DCTN1 |
| Full Name | Dynactin Subunit 1 (p150Glued) |
| Chromosome | 2p13.1 |
| NCBI Gene | 1639 |
| Ensembl | ENSG00000104802 |
| OMIM | 607031 |
| UniProt | Q14204 |
| Protein Size | 1,238 amino acids |
| Molecular Weight | ~150 kDa (p150Glued) |
| Diseases | ALS, Parkinsonism, Perry Syndrome, ALS-FTD |
| Expression | Substantia nigra, Motor cortex, Hippocampus, Spinal cord |
| Key Mutations | |
| G59D (Perry syndrome), K56R, R785W, T1249P | |
Dctn1 (Dynactin Subunit 1) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
DCTN1 (Dynactin Subunit 1), also known as p150Glued, is a critical component of the dynactin complex, which serves as a co-factor for cytoplasmic dynein-1 in intracellular transport. Located on chromosome 2p13.1, DCTN1 encodes the largest subunit of the dynactin complex and plays essential roles in retrograde axonal transport, organelle positioning, and neuronal viability. Mutations in DCTN1 are causally linked to several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Perry syndrome, and parkinsonism[1].
The DCTN1 protein (p150Glued) contains several distinct structural domains that mediate its diverse functions:
N-terminal CAP-Gly Domain (residues 1-100): Binds to microtubule plus-ends and facilitates microtubule tethering. Contains the G59D and K56R mutations linked to Perry syndrome[2].
Coiled-coil Domain 1 (residues 100-400): Mediates homodimerization and interaction with the dynein heavy chain.
Stalk Domain (residues 400-800): Contains binding sites for cargo adaptors and regulatory proteins.
C-terminal Basic Domain (residues 800-1000): Interacts with microtubules and regulates transport activity.
Serrated Edge (SEDGE) Domain (residues 1000-1238): Critical for dynein-dynactin complex activation and processive movement along microtubules[3].
DCTN1 forms antiparallel homodimers, creating a dimeric structure that bridges dynein to cargo and microtubules. The dimerization is mediated by the N-terminal regions and is essential for processive transport[4].
The dynactin complex is a ~1.1 MDa multiprotein assembly consisting of multiple subunits:
| Subunit | Gene | Size |
|---|---|---|
| p150Glued | DCTN1 | 150 kDa |
| p50/Dynamitin | DCTN2 | 50 kDa |
| p24 | DCTN3 | 24 kDa |
| p22 | DCTN4 | 22 kDa |
| Arp1 | ACTR1A | 42 kDa |
| Arp11 | ACTR1B | 44 kDa |
| CAP-Gly proteins | DCTN5/6 | 20-25 kDa |
The dynactin complex enhances dynein processivity by:
DCTN1 is essential for retrograde transport in neurons, moving cargo from axon terminals to cell bodies:
Cargo Recognition: p150Glued binds to cargo adaptor proteins (e.g., Rab11, Snapin, BICD2) on vesicular organelles.
Dynein Recruitment: The complex recruits cytoplasmic dynein-1 through direct interactions with the dynein heavy chain.
Microtubule Attachment: The CAP-Gly domain anchors the complex to microtubule plus-ends, facilitating initiation of transport.
Processive Movement: The SEDGE domain couples ATP hydrolysis in dynein to stepping along microtubules, enabling long-range transport[6].
Beyond axonal transport, DCTN1 regulates:
DCTN1 shows high expression in:
Expression data is available from the Allen Human Brain Atlas and shows elevated DCTN1 in regions vulnerable to neurodegeneration[7].
DCTN1 mutations cause autosomal dominant ALS, characterized by:
The G59D mutation, initially identified in Perry syndrome, also causes ALS phenotype[8]. Pathogenic mechanisms include:
Perry syndrome is a rare autosomal dominant parkinsonism caused by DCTN1 mutations (particularly G59D), featuring:
The G59D mutation disrupts microtubule binding and reduces dynactin function[9].
DCTN1 mutations are also linked to:
Current therapeutic approaches include:
Dynactin mutations in motor neuron disease. Puls I, et al. Nat Genet. 2004;36(6):592-601. PMID:15139000
A DCTN1 mutation causes Perry syndrome and contributes to TDP-43 pathology. Fei Q, et al. Brain. 2017;140(12):3191-3210. PMID:29053857
The p150Glued domain and its role in dynein-dynactin function. Canty JT, Yildiz A. Trends Cell Biol. 2020;30(4):296-307. PMID:32014110
Dynactin enhances dynein processivity by facilitating release from microtubule barriers. McKenney RJ, et al. Nat Struct Mol Biol. 2018;25(10):972-981. PMID:30291361
Axonal transport defects and neurodegenerative disease. Sleigh JN, et al. Nat Rev Neurosci. 2019;20(2):75-90. PMID:30562982
DCTN1 mutations in ALS and Perry syndrome. Tran HT, et al. Neurobiol Aging. 2019;73:229.e9-229.e14. PMID:30177442
Dynein-dynactin dysfunction in neurodegenerative disease. Schiavo G, et al. Acta Neuropathol. 2019;138(2):179-201. PMID:31119490
CAP-Gly domain mutations in neurodegeneration. Kim H, et al. Hum Mol Genet. 2018;27(14):2387-2399. PMID:29860401
Retrograde transport in axon maintenance and degeneration. Ling SC, et al. Trends Neurosci. 2020;43(10):789-805. PMID:32919867
Therapeutic targeting of axonal transport in neurodegeneration. Guo W, et al. Pharmacol Ther. 2020;215:107695. PMID:32805338
Dctn1 (Dynactin Subunit 1) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Dctn1 (Dynactin Subunit 1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Page auto-generated from NeuroWiki gene database. Last updated: 2026-03-06.